Conference abstract · 10 Mar 2016
Conference abstractPublished 7 Dec 2015
Rational design of immune checkpoints’ small molecule inhibitors
University of Alberta, Canada
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
T lymphocytes preserve the immunological balance between defending against viral infection and preventing continual activated immune responses. While T cellsâÂ?Â? specificity against cancer or viral infection is determined by the interaction between the T-cell receptor complex (TCR) and antigenic peptides bound in surface major histocompatibility complex (MHC) molecules, the full activation of T cells requires a second signal obtained by the binding of the co-receptor CD28 on T cells to CD80/86 molecules on activated antigen presenting cells (APCs). Once mobilized, T cells also express other receptors that inhibit their proliferation and cytokine production, known as immune checkpoints. Among these receptors are Cytotoxic T Lymphocyte Antigen-4 (CTLA-4), programmed death-1 (PD-1) and T cell immunoglobulin mucin-3 (TIM-3) and many others. Blocking the interactions between these receptors and their ligands emerged as a âÂ?Â?game changerâÂ?Â? in immunotherapy, with antibodies directed toward PD-1, for example, being selected as âÂ?Â?drug of the yearâÂ?Â? for 2013 by Science. More importantly, combination blockage of multiple co-inhibitory pathways has a greater efficacy by preventing accumulation of the unblocked negative co-receptor, allowing T cells to continue to survive, proliferate, and carry out effector functions within infected cells. This talk will focus on PD-1 and will describe for the first time two accurate models for human PD-1 bound to its two human ligands. The talk will also demonstrate how these two models are being used to rationally design small molecule inhibitors for the Pd-1 pathway.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 2014
Do We Need Small Molecule Inhibitors for the Immune Checkpoints?
Conference abstract · 15 Oct 2013
Towards rational design of fluorine substitution in small molecule inhibitors targeting protein-protein interactions
Conference abstract · 2017
Rational design of small molecule immune checkpoints' inhibitors: The PD-1 challenge
Conference abstract · 20 Sep 2018
Structure-Based Discovery of TRAF-STOPS: Small Molecule Inhibitors of the CD40-TRAF6 Interaction to block Inflammatory Pathways in Atherosclerosis and other Immune-Modulated Pathologies
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
How is really working adaptive immune system in mammals? A novel conception and reverse pathway theory, which will bring novel multibillion super-antibody (sab) technology for curing of all of infectious diseases and cancer!
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Khaled Barakat”

